Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell’s fault. Endocr Relat Cancer 2002; 9:61 - 73; http://dx.doi.org/10.1677/erc.0.0090061; PMID: 11914183
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59:572 - 83; http://dx.doi.org/10.1016/j.eururo.2011.01.025; PMID: 21315502
   PubMed Web of Science ®Google Scholar
• Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24:1967 - 2000; http://dx.doi.org/10.1101/gad.1965810; PMID: 20844012
   PubMed Web of Science ®Google Scholar
• Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60:753 - 66; http://dx.doi.org/10.1016/j.eururo.2011.06.035; PMID: 21719191
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5:522 - 31; http://dx.doi.org/10.1038/nrg1379; PMID: 15211354
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11:597 - 610; PMID: 20661255
   PubMed Web of Science ®Google Scholar
• Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005; 4:1179 - 84; http://dx.doi.org/10.4161/cc.4.9.2032; PMID: 16096373
   PubMed Web of Science ®Google Scholar
• Bueno MJ, Pérez de Castro I, Malumbres M. Control of cell proliferation pathways by microRNAs. Cell Cycle 2008; 7:3143 - 8; http://dx.doi.org/10.4161/cc.7.20.6833; PMID: 18843198
   PubMed Web of Science ®Google Scholar
• Hassan O, Ahmad A, Sethi S, Sarkar FH. Recent updates on the role of microRNAs in prostate cancer. J Hematol Oncol 2012; 5:9; http://dx.doi.org/10.1186/1756-8722-5-9; PMID: 22417299
   PubMed Web of Science ®Google Scholar
• Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12:861 - 74; http://dx.doi.org/10.1038/nrg3074; PMID: 22094949
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4:143 - 59; http://dx.doi.org/10.1002/emmm.201100209; PMID: 22351564
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302:1 - 12; http://dx.doi.org/10.1016/j.ydbio.2006.08.028; PMID: 16989803
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834 - 8; http://dx.doi.org/10.1038/nature03702; PMID: 15944708
   PubMed Web of Science ®Google Scholar
• Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67:6130 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-07-0533; PMID: 17616669
   PubMed Web of Science ®Google Scholar
• Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27:1788 - 93; http://dx.doi.org/10.1038/sj.onc.1210809; PMID: 17891175
   PubMed Web of Science ®Google Scholar
• Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A 2011; 108:4394 - 9; http://dx.doi.org/10.1073/pnas.1014720108; PMID: 21368194
   PubMed Web of Science ®Google Scholar
• Shan G, Li Y, Zhang J, Li W, Szulwach KE, Duan R, et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008; 26:933 - 40; http://dx.doi.org/10.1038/nbt.1481; PMID: 18641635
   PubMed Web of Science ®Google Scholar
• Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 2009; 41:365 - 70; http://dx.doi.org/10.1038/ng.317; PMID: 19219043
   PubMed Web of Science ®Google Scholar
• Felici A, Pino MS, Carlini P. A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) 2012; 3:85; http://dx.doi.org/10.3389/fendo.2012.00085; PMID: 22826702
   PubMedGoogle Scholar
• Hamberg P, Verhagen PC, de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?. Eur J Cancer 2008; 44:1193 - 7; http://dx.doi.org/10.1016/j.ejca.2008.04.005; PMID: 18448326
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 2008; 19:Suppl 7 vii91 - 5; http://dx.doi.org/10.1093/annonc/mdn473; PMID: 18790987
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513 - 20; http://dx.doi.org/10.1056/NEJMoa041318; PMID: 15470214
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al, TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502 - 12; http://dx.doi.org/10.1056/NEJMoa040720; PMID: 15470213
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al, COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983 - 92; http://dx.doi.org/10.1016/S1470-2045(12)70379-0; PMID: 22995653
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• McDermott AM, Heneghan HM, Miller N, Kerin MJ. The therapeutic potential of microRNAs: disease modulators and drug targets. Pharm Res 2011; 28:3016 - 29; http://dx.doi.org/10.1007/s11095-011-0550-2; PMID: 21818713
   PubMed Web of Science ®Google Scholar
• Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets 2012; 16:Suppl 2 S103 - 9; http://dx.doi.org/10.1517/14728222.2011.650632; PMID: 22443195
   PubMed Web of Science ®Google Scholar
• Bhanot SK, Singh M, Chatterjee NR. The chemical and biological aspects of fluoroquinolones: reality and dreams. Curr Pharm Des 2001; 7:311 - 35; http://dx.doi.org/10.2174/1381612013398059; PMID: 11254892
   PubMed Web of Science ®Google Scholar
• Schaeffer AJ. The expanding role of fluoroquinolones. Am J Med 2002; 113:Suppl 1A 45S - 54S; http://dx.doi.org/10.1016/S0002-9343(02)01059-8; PMID: 12113871
   PubMedGoogle Scholar
• Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer 2010; 1:381 - 7; http://dx.doi.org/10.1177/1947601910371978; PMID: 20657750
   PubMedGoogle Scholar
• Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 2012; 11:1166 - 73; http://dx.doi.org/10.1158/1535-7163.MCT-12-0100; PMID: 22402125
   PubMed Web of Science ®Google Scholar
• Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009; 28:1714 - 24; http://dx.doi.org/10.1038/onc.2009.19; PMID: 19252524
   PubMed Web of Science ®Google Scholar
• Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008; 14:417 - 24; http://dx.doi.org/10.1261/rna.874808; PMID: 18174313
   PubMed Web of Science ®Google Scholar
• Xu Y, Fang F, Zhang J, Josson S, St Clair WH, St Clair DK. miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS One 2010; 5:e14356; http://dx.doi.org/10.1371/journal.pone.0014356; PMID: 21203553
   PubMedGoogle Scholar
• Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377:114 - 9; http://dx.doi.org/10.1016/j.bbrc.2008.09.086; PMID: 18834855
   PubMed Web of Science ®Google Scholar
• Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 2008; 105:13421 - 6; http://dx.doi.org/10.1073/pnas.0801613105; PMID: 18755897
   PubMed Web of Science ®Google Scholar
• Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98:604 - 10; http://dx.doi.org/10.1038/sj.bjc.6604199; PMID: 18212746
   PubMed Web of Science ®Google Scholar
• Song Y, Shiota M, Tamiya S, Kuroiwa K, Naito S, Tsuneyoshi M. The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. Histopathology 2011; 58:773 - 80; http://dx.doi.org/10.1111/j.1365-2559.2011.03797.x; PMID: 21438903
   PubMed Web of Science ®Google Scholar
• Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67:6612 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-07-0085; PMID: 17638871
   PubMed Web of Science ®Google Scholar
• Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, et al. Androgen regulation of micro-RNAs in prostate cancer. Prostate 2011; 71:604 - 14; http://dx.doi.org/10.1002/pros.21276; PMID: 20945501
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103:2257 - 61; http://dx.doi.org/10.1073/pnas.0510565103; PMID: 16461460
   PubMed Web of Science ®Google Scholar
• Pearson H, Stirling D. DNA extraction from tissue. Methods Mol Biol 2003; 226:33 - 4; PMID: 12958476
   PubMedGoogle Scholar
• Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009; 10:R64; http://dx.doi.org/10.1186/gb-2009-10-6-r64; PMID: 19531210
   PubMed Web of Science ®Google Scholar